Salmon and fennel at its best.

Speech by Mr Mugur Isărescu, Governor of the National Bank of Romania, Bucharest, 29 April 2020.

Every year SOLIDWORKS hosts one of the largest engineering conferences in the world. Since SOLIDWORKS World 2000, Model Mania® has been an attraction for many engineers wanting to show off their SOLIDWORKS skills. Model Mania, for those not familiar, is a

Author information

The post 21 Years of Model Mania® appeared first on SOLIDWORKS Tech Blog.

A local church gets excited about bringing the gospel of Christ to their small community.

Leishmania major is the causative agent of cutaneous leishmaniasis (CL). No human vaccine is available for CL and current drug regimens present several drawbacks such as emerging resistance, severe toxicity, medium effectiveness, and/or high cost. Thus, the need for better treatment options against CL is a priority. In the present study, we validate the enzyme methionine aminopeptidase-1 (MetAP1), a metalloprotease that catalyzes the removal of N-terminal methionine from peptides and proteins, as a chemotherapeutic target against CL infection. The in vitro antileishmanial activity of eight novel MetAP1 inhibitors (OJT001-OJT008) were investigated. Three compounds OJT006, OJT007, and OJT008 demonstrated potent anti-proliferative effect in macrophages infected with L. major amastigotes and promastigotes at submicromolar concentrations, with no cytotoxicity against host cells. Importantly, the leishmanicidal effect was diminished by almost 10-fold in transgenic L. major promastigotes overexpressing MetAP1_LM in comparison to wild-type promastigotes. Furthermore, the in vivo activity of OJT006, OJT007, and OJT008 were investigated in L. major-infected BALB/c mice. In comparison to the control group, OJT008 significantly decreased footpad parasite load by 86%, and exhibited no toxicity against in treated mice. We propose MetAP1 inhibitor OJT008 as a potential chemotherapeutic candidate against CL infection caused by L. major infection.

Treatment of dogs naturally infected with Leishmania infantum using meglumine antimoniate (MA) encapsulated in conventional liposomes (LC) in association with allopurinol has been previously reported to promote marked reduction in the parasite burden in the main infection sites. Here, a new assay in naturally infected dogs was performed using a novel liposome formulation of MA consisting of a mixture of conventional and long-circulating (PEGylated) liposomes (LCP), with expected broader distribution among affected tissues of the mononuclear phagocyte system. Experimental groups of naturally infected dogs were as follows: LCP+Allop, receiving LCP intravenously as 2 cycles of 6 doses (6.5 mg Sb/kg/dose) at 4-day intervals, plus allopurinol at 30 mg/kg/12 h p.o. during 130 days; LC+Allop, receiving LC intravenously as 2 cycles of 6 doses (6.5 mg Sb/kg/dose), plus allopurinol during 130 days; Allop, treated with allopurinol only; non-treated control. Parasite loads were evaluated by quantitative PCR in liver, spleen and bone marrow and by immunohistochemistry in the ear skin, before, just after treatment and 4 months later. LCP+Allop and LC+Allop groups, but not the Allop group, showed significant suppression of the parasites in the liver, spleen and bone marrow 4 months after treatment, compared to the pre-treatment period or the control group. Only LCP+Allop group showed significantly lower parasite burden in the skin, in comparison to the control group. On the basis of clinical staging and parasitological evaluations, LCP formulation exhibited a more favorable therapeutic profile, when compared to LC one, being therefore promising for treatment of canine visceral leishmaniasis.

Peroxidases are a group of heterogeneous family of enzyme that plays diverse biological functions. Ascorbate peroxidase is a redox enzyme that is reduced by trypanothione, which plays a central role in the redox defence system of Leishmania. In view of developing new and novel therapeutics, we have performed in silico studies in order to search for ligand library and identification of new drug candidates and its physiological role against promastigotes and intracellular amastigotes of Leishmania donovani. Our results demonstrated that the selected inhibitor ZINC96021026 has significant anti-leishmanial effect and effectively killed both free and intracellular forms of the parasite. ZINC96021026 was found to be identical to ML-240, a selective inhibitor of Valosin-containing protein (VCP) or p97, a member of AAA-ATPase protein family which was derived from the scaffold of DBeQ, targeting the D2-ATPase domain of the enzyme. ZINC96021026 (ML-240) thus have broad range of cellular functions, thought to be derived from its ability to unfold proteins or disassemble protein complexes besides inhibiting the ascorbate peroxidase activity. ML-240 may inhibits the parasite's ascorbate peroxidase leading to extensive apoptosis and inducing generation of reactive oxygen species. Taken together, our results demonstrated that ML-240 could be an attractive therapeutic option for treatment against leishmaniasis.

France beat Croatia to earn a final tournament debut, as they joined Serbia, Romania and Poland in qualifying for UEFA Futsal EURO 2018 via the play-offs.

Romania and Slovakia will stage the U19 EURO final tournaments in 2021 and 2022 respectively.

Team news, coaches' views, form guide and key stats as Germany meet Romania.

• Footballers use popularity to advise expats to stay away to safeguard health
• Bucharest’s two biggest clubs fund life-saving equipment for capital’s hospitals
• National stadium converted to 24/7 emergency helpline centre

The portfolio comprises three properties in the capital Bucharest, and one in Timisoara, a city in the west of the country.

Speaking at the Indian Express e-Adda from the US, Subramanian said that distribution of food and cash are the two key tools India should be using to help people tide over the crisis.

In an interview to India Today channel, the CEA said: “About $4 trillion of money tracks these (global) bond indices. India is expected to get a weight of around 1.5-3%. Even if you take 1.5%, that translates into $60 billion.”

1 Seychellois Rupee = 0.2594 Romanian Leu

1 Trinidad and Tobago Dollar = 0.659 Romanian Leu

1 Swedish Krona = 0.4557 Romanian Leu

1 Slovak Koruna = 0.2005 Romanian Leu

1 Serbian Dinar = 0.0411 Romanian Leu

1 Polish Zloty = 1.0591 Romanian Leu

1 Qatari Rial = 1.2231 Romanian Leu

1 Indian Rupee = 0.059 Romanian Leu

1 Pakistani Rupee = 0.0279 Romanian Leu

1 Sierra Leonean Leone = 0.0005 Romanian Leu

1 New Taiwan Dollar = 0.1492 Romanian Leu

1 Thai Baht = 0.1391 Romanian Leu

1 Turkish Lira = 0.6282 Romanian Leu

1 Singapore Dollar = 3.1524 Romanian Leu

1 Mauritian Rupee = 0.1121 Romanian Leu

1 Nepalese Rupee = 0.0368 Romanian Leu

1 Bangladeshi Taka = 0.0524 Romanian Leu

1 Moldovan Leu = 0.2498 Romanian Leu

1 Colombian Peso = 0.0011 Romanian Leu

1 Uruguayan Peso = 0.1032 Romanian Leu

1 Uzbekistan Som = 0.0004 Romanian Leu

1 Russian Ruble = 0.0607 Romanian Leu

1 Iraqi Dinar = 0.0037 Romanian Leu

1 Cayman Islands Dollar = 5.3427 Romanian Leu

1 Swiss Franc = 4.5865 Romanian Leu

1 CFA Franc BCEAO = 0.0074 Romanian Leu

1 Vietnamese Dong = 0.0002 Romanian Leu

1 Macedonian Denar = 0.0784 Romanian Leu

1 Zambian Kwacha = 0.0009 Romanian Leu

1 South Korean Won = 0.0037 Romanian Leu

1 Jordanian Dinar = 6.2768 Romanian Leu

1 Lebanese Pound = 0.0029 Romanian Leu

1 Bahraini Dinar = 11.7759 Romanian Leu